Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in …

Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine
encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome …

Background We have previously estimated that respiratory syncytial virus (RSV) was associated
with 22% of all episodes of (severe) acute lower respiratory infection (ALRI) resulting in …

Background While the Northern Hemisphere experiences the effects of the 2009 pandemic
influenza A (H1N1) virus, data from the recent influenza season in the Southern Hemisphere …

Pandemic influenza viruses often cause severe disease in middle-aged adults without
preexisting comorbidities. The mechanism of illness associated with severe disease in this age …

Background Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19)
remain elusive. Among them, convalescent plasma administered to hospitalized …

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in
infants and young children. Administration of a formalin inactivated vaccine against RSV to …

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. A formalin-inactivated
RSV vaccine was used to immunize children and elicited nonprotective, …

Background Whether vaccination during pregnancy could reduce the burden of respiratory
syncytial virus (RSV)–associated lower respiratory tract illness in newborns and infants is …

Background Respiratory syncytial virus (RSV) infection causes considerable illness in older
adults. The efficacy and safety of an investigational bivalent RSV prefusion F protein–based (…